Emma H. Gray

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 31, 2026

Improving Appendicitis Prediction in Children Using the Paediatric Appendicitis Score (PAS): A Three-Year Retrospective Study.

Improving Appendicitis Prediction in Children Using the Paediatric Appendicitis Score (PAS): A Three-Year Retrospective Study.

Journal: Cureus
Published: August 26, 2025

Brain health - time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report.

Brain health - time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report.

Journal: Multiple sclerosis and related disorders
Published: April 17, 2025

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)
Published: March 23, 2025

The first global landscape analysis of multiple sclerosis research funding.

The first global landscape analysis of multiple sclerosis research funding.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 31, 2024

Research Priorities for Autonomous Sensory Meridian Response: An Interdisciplinary Delphi Study.

Research Priorities for Autonomous Sensory Meridian Response: An Interdisciplinary Delphi Study.

Journal: Multisensory research
Published: June 18, 2024

A novel multisite model to facilitate hepatitis C virus elimination in people experiencing homelessness.

A novel multisite model to facilitate hepatitis C virus elimination in people experiencing homelessness.

Journal: JHEP reports : innovation in hepatology
Published: May 04, 2024

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

Journal: EBioMedicine
Published: December 18, 2023

Enhancing involvement of people with multiple sclerosis in clinical trial design.

Enhancing involvement of people with multiple sclerosis in clinical trial design.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 09, 2023

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Journal: The Lancet. Oncology
Published: January 23, 2023

Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.

Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.

Journal: Inflammatory bowel diseases
Published: October 27, 2022

Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.

Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.

Journal: Immunotherapy
Published: July 07, 2022
Showing 1-12 of 45

Last Updated: 09/26/2026